ArticleClinical rheumatology2026
The rising global burden of gout attributable to kidney dysfunction: a 30-year trend analysis and projections to 2036.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Uric Acid as a Redox Switch in Gout: Linking Xanthine Oxidoreductase-Derived ROS, NLRP3 Inflammasome Activation and Emerging Ferroptotic Mechanisms.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRenal impairment and gout are mutually exacerbating conditions, yet the global burden of gout attributable to kidney dysfunction remains unquantified. This study examines trends in gout-related disability associated with renal impairment to inform global health strategies.
methodsData were extracted from the global burden of disease (GBD) 2021. The age-standardized disability-adjusted life years (DALYs) rate and estimated annual percentage change (EAPC) were analysed. A Bayesian Age-Period-Cohort (BAPC) model was implemented to project disease burden. Health inequality analyses were conducted to assess absolute and relative inequalities across socio-demographic index (SDI) regions.
resultsThe global burden of gout attributable to renal impairment was estimated at 200,033 DALYs (95% Uncertainty Interval (UI): 125,245-296,812) globally. Age-standardized DALY rate increased from 1.47 (95% UI: 0.91-2.21) per 100,000 population in 1990 to 2.36 (95% UI: 1.48-3.50) in 2021 (EAPC 0.67). Significant geographical disparities were observed, with inequality analysis revealing a disproportionate concentration in high SDI regions. Male exhibited elevated age-standardized DALYs compared to females, with both genders exhibiting progressive age-dependent increases. Projection models indicated a potential decline trend in the global burden of renal impairment-associated gout.
conclusionsThis study systematically quantifies the global burden of gout attributable to renal impairment, revealing significant disparities across regions, genders, and age. The burden was predominantly concentrated in high-SDI regions, with male sex and advanced age identified as significant individual-level risk factors. These findings highlight the importance of tailored management strategies for high-risk populations, particularly elderly individuals with renal impairment. Key Points • An increasing global burden of gout attributable to renal impairment was observed from 1990 to 2021. Substantial geographical heterogeneity was noted across countries and regions, with the burden showing a positive correlation with the Socio-demographic Index. The disparity in disease burden between high and low SDI regions has continued to widen. • A distinct age-dependent increase in disease burden is observed among gout patients with renal impairment. Elderly individuals frequently present with multiple comorbidities, introducing complex challenges in clinical management. Enhanced screening and optimized treatment strategies for this population are urgently required. • Non-genetic determinants, including healthcare accessibility, diagnostic practices, environmental influences, and dietary patterns, may exert a more substantial influence on gout cases attributable to renal impairment. • Projection models indicate that the future global burden of gout attributable to renal impairment is likely to decline.
Indexed as
Identifiers
42185610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.